also
known
bispecif
tcell
engag
biteh
antibodi
develop
treatment
patient
cancer
express
carcinoembryon
antigen
cea
bind
cea
cancer
cell
cell
induc
tcell
mediat
kill
cancer
cell
understand
molecular
basi
human
cea
recognit
polymorph
splice
form
cea
may
affect
activ
map
epitop
cea
use
mutagenesi
homolog
model
approach
found
recogn
conform
epitop
domain
compris
amino
acid
critic
residu
f
n
v
g
p
e
n
two
nonsynonym
singlenucleotid
polymorph
snp
identifi
epitop
region
found
low
homozygos
rate
search
nation
center
biotechnolog
inform
genbankh
databas
identifi
singl
previous
uncharacter
mrna
splice
variant
cea
lack
portion
ntermin
domain
domain
larg
portion
domain
realtim
quantit
polymeras
chain
reaction
analysi
multipl
cancer
show
widespread
express
fulllength
cea
tumor
less
frequent
concord
express
cea
splice
variant
epitop
larg
absent
cea
splice
variant
bind
mediat
tcell
kill
cell
sole
express
form
cea
addit
splice
variant
interfer
bind
activ
coexpress
fulllength
cea
thu
may
broadli
target
ceaposit
tumor
without
regard
express
short
splice
variant
cea
togeth
data
suggest
activ
neither
impact
snp
splice
variant
cea
carcinoembryon
antigen
cea
glycosyl
human
oncofet
antigen
belong
cearel
cell
adhes
molecul
ceacam
famili
immunoglobulin
ig
gene
superfamili
cea
close
relat
carcinoembryon
antigen
suggest
mediat
cellcel
adhes
facilit
bacteri
colon
intestin
protect
colon
microbi
infect
bind
trap
infecti
microorgan
cea
express
low
level
normal
tissu
epitheli
origin
polar
manner
found
lumin
portion
cell
basolater
surfac
contrast
express
cea
frequent
high
carcinoma
includ
colon
pancreat
gastric
esophag
lung
breast
uterin
ovarian
endometri
cancer
cancer
cell
lose
polar
lumin
express
cea
activ
cleav
cea
surfac
phospholipas
action
result
serum
concentr
cea
approach
mgml
serum
cea
level
may
monitor
detect
respons
anticanc
therapi
diseas
recurr
colorect
cancer
serv
prognost
indic
patient
gastrointestin
cancer
elev
level
indic
poor
prognosi
correl
reduc
overal
surviv
cellbound
cea
serv
target
tumor
imag
anticanc
therapi
clinic
studi
demonstr
radiolabel
anticea
antibodi
antibodi
fragment
food
drug
administrationapprov
anticea
fab
arcitumomab
ceascanh
success
use
imag
reagent
specif
local
ceaexpress
solid
cancer
anticea
radioimmunoconjug
antibodi
also
shown
potenti
efficaci
treatment
patient
metastat
colorect
cancer
addit
ceaspecif
antibodydirect
enzym
prodrug
therapi
ceabas
vaccin
approach
develop
treat
cancer
novel
ceadirect
therapi
develop
ceatarget
bispecif
singlechain
antibodi
bispecif
tcell
engag
bite
class
term
also
known
bite
antibodi
uniqu
subclass
bispecif
antibodi
contain
one
singl
chain
variabl
fragment
scfv
specif
tumor
associ
antigen
molecularli
fuse
anoth
scfv
specif
cell
highli
potent
specif
tumor
cell
lysi
trigger
bite
antibodi
bind
epitop
simultan
result
direct
cell
tumor
cell
activ
cell
cell
receptor
tcr
complex
notabl
activ
cell
independ
tcr
specif
peptid
antigen
present
costimulatori
signal
result
cell
activ
granzym
perforin
mobil
tumor
cellt
cell
interfac
mediat
apoptot
kill
target
cell
fa
ligand
express
may
also
contribut
induct
apoptosi
engag
fa
tumor
cell
bite
antibodi
activ
cell
subset
subset
cell
contribut
tumor
cell
kill
rel
low
effector
cell
target
tumor
cell
e
ratio
cytokin
secret
upregul
cell
surfac
receptor
cell
measur
experiment
use
antibodi
recogn
occur
simultan
accompani
tumor
cell
kill
potenti
cell
activ
prolifer
facilit
subsequ
engag
kill
addit
tumor
cell
bound
bite
antibodi
bite
antibodi
induc
potent
lysi
human
cancer
cell
line
vitro
also
shown
mediat
kill
primari
human
tumor
cell
cancer
patient
cell
ex
vivo
furthermor
bite
antibodi
promot
vivo
tumor
regress
numer
preclin
anim
model
shown
sign
clinic
benefit
patient
cancer
compos
human
singlechain
antibodi
recogn
human
cea
connect
short
flexibl
linker
deimmun
singlechain
antibodi
specif
share
characterist
bite
antibodi
class
describ
specif
bind
cea
ceacam
famili
member
upon
concurr
bind
cea
cancer
cell
cell
mediat
cell
activ
subsequ
kill
ceaexpress
target
cell
perforinand
granzymedepend
manner
insensit
concentr
mgml
solubl
cea
furthermor
intraven
subcutan
administr
anticanc
activ
sever
combin
immunodefici
mous
xenograft
model
variou
human
cancer
growth
inhibit
cancer
conting
presenc
unstimul
human
cell
express
cea
cancer
cell
current
phase
clinic
trial
clinicaltrialsgov
identifi
treatment
gastrointestin
adenocarcinoma
understand
molecular
basi
human
cea
recognit
impact
amino
acid
polymorph
splice
variant
cea
activ
sought
identifi
cea
domain
critic
residu
involv
bind
ceaspecif
arm
human
version
murin
antibodi
bind
epitop
unknown
map
epitop
use
mutagenesi
comput
model
approach
investig
impact
cea
splice
variant
lack
larg
portion
identifi
epitop
could
bind
activ
plasmid
contain
fulllength
cea
sequenc
purchas
open
biosystem
thermo
fisher
scientif
huntsvil
al
cea
complementari
dna
cdna
subclon
use
sequenc
specif
primer
modifi
version
lentivir
vector
system
bioscienc
mountain
view
ca
puromycinresist
casett
replac
blasticidinresist
cassett
cea
sequenc
verifi
dna
sequenc
plasmid
contain
sequenc
cea
splice
variant
cdna
clone
purchas
imagen
gmbh
sourc
bioscienc
uk
limit
nottingham
uk
associ
b
bridg
intern
cupertino
ca
cea
splice
variant
clone
puromycin
resist
lentivir
vector
system
bioscienc
use
sequencespecif
primer
result
clone
sequenceverifi
freestyl
human
embryon
kidney
f
cell
american
type
cultur
collect
manassa
va
cultur
freestyl
express
medium
life
technologiesinvitrogen
carlsbad
ca
dihydrofol
reductas
defici
dhfr
chines
hamster
ovari
cho
cell
cho
dhfrcell
american
type
cultur
collect
manassa
va
cultur
rpmi
media
invitrogen
contain
fetal
bovin
serum
fb
invitrogen
humidifi
cell
cultur
incub
co
cho
cell
express
cea
splice
variant
cho
sv
cea
creat
infect
cho
dhfrcell
splice
variant
lentivir
vector
select
cultur
medium
contain
mgml
puromycin
emd
chemic
group
merck
kgaa
darmstadt
germani
hour
cho
cell
express
fulllength
cea
sequenc
cho
fl
cea
creat
infect
cho
dhfrcell
lentivir
express
vector
select
cultur
medium
contain
mgml
blasticidin
invitrogen
day
likewis
cell
express
cea
splice
variant
fulllength
cea
cho
flsv
cea
creat
infect
cea
splice
variantexpress
cell
lentivir
vector
follow
blasticidin
select
specif
monoclon
antibodi
mab
clone
purchas
genovac
gmbh
aldevron
freiburg
germani
propidium
iodid
pi
purchas
sigmaaldrich
st
loui
mo
construct
product
control
bite
bite
describ
twenti
pancreat
primari
tumor
purchas
asterand
inc
detroit
mi
panel
includ
adenocarcinoma
stage
iiv
pancreat
endocrin
tumor
benign
pancreat
adenoma
four
pancreat
tumor
tissu
sampl
match
normal
adjac
pancreat
tissu
sampl
patient
age
rang
year
sampl
freshli
frozen
collect
initi
cancer
treatment
tumor
sampl
macrodissect
remov
normal
tissu
tumor
puriti
sampl
greater
normal
sampl
macrodissect
remov
nonglandular
tissu
cancer
tissu
cdna
array
colon
cancer
gastroesophag
cancer
pancreat
cancer
lung
cancer
breast
cancer
purchas
origen
technolog
rockvil
md
array
contain
cdna
normal
tissu
cancer
tissu
tumor
stage
rang
stage
iv
tumor
tissu
compris
tumor
cell
lyse
ripa
lysi
buffer
boston
bioproduct
ashland
result
protein
quantifi
use
bca
protein
assay
kit
thermo
fisher
scientif
huntsvil
al
cell
lysat
mix
nupageh
ld
ld
sampl
buffer
invitrogen
concentr
ten
microgram
total
protein
lysat
analyz
precast
nupageh
novexh
polyacrylamid
bistri
gel
invitrogen
togeth
novexh
sharp
prestain
protein
standard
invitrogen
use
nupageh
trisacet
sd
run
buffer
invitrogen
protein
gel
transfer
polyvinyliden
fluorid
membran
use
ibloth
dri
blot
system
invitrogen
nupageh
transfer
buffer
invitrogen
contain
methanol
block
bovin
serum
albumin
sigma
pb
ph
invitrogen
detect
cea
blot
probe
overnight
mgml
mab
clone
genovac
wash
pb
ph
contain
subsequ
probe
hour
horseradish
peroxidaseconjug
donkey
antimous
igg
secondari
antibodi
jackson
immunoresearch
laboratori
west
grove
pa
wash
pb
ph
contain
blot
expos
supersign
west
pico
chemiluminesc
substrat
thermo
fisher
scientif
expos
biomax
ms
kodak
film
sigma
detect
chemiluminesc
result
bound
antibodi
equal
amount
protein
load
lane
gel
control
detect
glyceraldehyd
dehydrogenas
gapdh
protein
use
rabbit
antihuman
gapdh
polyclon
antibodi
trevigen
gaithersburg
md
follow
horseradish
peroxidaseconjug
donkey
antirabbit
igg
jackson
immunoresearch
cdna
encod
cea
delet
variant
del
swap
variant
koa
kob
koc
kia
kib
kic
see
figur
domain
definit
variant
nomenclatur
assembl
amplifi
overlap
extens
polymeras
chain
reaction
pcr
use
inhous
fulllength
cea
cdna
clone
pneo
human
ceagpi
templat
cea
variant
fulllength
cea
cdna
clone
mammalian
express
vector
invitrogen
express
vector
encod
cea
delet
swap
mutant
transient
transfect
express
glycophosphatidyl
inositol
gpi
anchor
protein
use
freestyl
f
cell
invitrogen
one
day
prior
transfect
f
cell
seed
densiti
cellsml
three
half
microgram
express
vector
transfect
ml
suspens
f
cell
use
ml
transfect
reagent
invitrogen
transfect
cell
incub
mgml
hour
detect
bound
possess
sixhistidin
tag
carboxyterminu
cell
wash
three
time
pb
incub
mgml
alexa
fluorh
antipentahi
antibodi
qiagen
valencia
ca
minut
analyz
bind
use
lsrii
flow
cytomet
bd
bioscienc
san
jose
ca
express
cea
delet
mutant
monitor
goat
anticea
polyclon
antibodi
r
system
minneapoli
mn
detect
rphycoerythrinconjug
antigoat
igg
invitrogen
sitedirect
mutagenesi
comput
homolog
model
implement
identifi
amino
acid
within
cea
critic
bind
follow
amino
acid
epitopecontain
segment
c
domain
see
result
discuss
section
differ
domain
mutat
cluster
individu
encod
correspond
amino
acid
model
use
templat
engin
two
addit
mutant
two
mutant
substitut
cluster
v
g
p
e
n
domain
correspond
cluster
domain
kovgpein
graft
cluster
f
n
v
g
p
e
n
domain
domain
kiftnvgpein
respect
mutant
assembl
overlap
extens
pcr
use
truncat
mutant
templat
encod
ntermin
domain
domain
gpi
region
clone
mammalian
express
vector
invitrogen
express
mutant
bind
analys
conduct
list
delet
swap
mutant
fulllength
mrna
transcript
sequenc
cea
cea
splice
variant
retriev
ncbi
refer
sequenc
databas
fulllength
cea
assay
target
splice
junction
exon
design
gene
specif
probe
cea
splice
variant
assay
target
splice
junction
exon
exon
design
gene
specif
probe
primerprob
import
primer
express
appli
biosystem
foster
citi
ca
softwar
tool
ensur
optim
design
util
taqman
gene
express
assay
procedur
probe
design
incorpor
minor
groov
bind
moieti
mgb
label
fluoresc
dye
fam
detect
nonfluoresc
quencher
primer
probe
custom
order
appli
biosystem
sequenc
primerprob
combin
follow
cea
fulllength
sequenc
probe
sequenc
forward
primer
sequenc
revers
primer
cea
splice
variant
sequenc
probe
cea
sequenc
forward
primer
sequenc
revers
primer
realtim
qpcr
conduct
biomark
tm
dynam
array
microfluid
system
fluidigm
corpor
south
san
francisco
ca
use
rna
isol
frozen
pancreat
tissu
first
total
rna
extract
frozen
slide
section
pancreat
tissu
classifi
normal
nat
normal
adjac
tumor
adenocarcinoma
benign
adenoma
endocrin
tumor
use
zr
rna
microprep
kit
zymo
research
orang
ca
rna
puriti
concentr
determin
spectrophotometr
rna
qualiti
assess
agil
bioanalyz
use
rna
nano
labchiph
agil
technolog
santa
clara
ca
singl
strand
cdna
gener
total
pancrea
rna
use
superscripth
iii
firststrand
synthesi
supermix
invitrogen
cdna
sampl
preamplifi
use
taqman
preamp
master
mix
invitrogen
accord
manufactur
instruct
reaction
cycl
recommend
program
cycl
dilut
te
buffer
preamplifi
cdna
either
util
immedi
store
process
sampl
taqman
gene
express
assay
appli
biosystem
carlsbad
ca
load
onto
dynam
array
fluidigm
accord
manufactur
instruct
prepar
array
load
biomark
tm
realtim
pcr
system
fluidigm
thermal
cycl
min
follow
cycl
sec
min
upon
complet
qpcr
fluidigm
realtim
pcr
analysi
softwar
use
gener
threshold
cycl
ct
valu
ct
cutoff
valu
sampl
consid
posit
sampl
consid
neg
transcript
express
empir
select
tissuescan
tm
diseas
tissu
quantit
polymeras
chain
reaction
qpcr
array
origen
technolog
rockvil
md
employ
determin
express
fulllength
cea
splice
variant
sv
transcript
normal
cancer
tissu
variou
stage
grade
tissu
cdna
array
lyophil
cdna
resuspend
ml
ribonucleasefre
water
plate
seal
vortex
centrifug
g
min
ensur
resuspens
full
cdna
sampl
mixtur
taqman
assay
appli
biosystem
creat
accord
protocol
suppli
manufactur
preamplif
one
cycl
min
follow
cycl
min
subsequ
amplif
transcript
detect
one
cycl
sec
follow
cycl
sec
specif
target
transcript
carri
use
abi
fast
real
time
pcr
instrument
appli
biosystem
upon
complet
qpcr
sd
softwar
ericsson
stockholm
sweden
use
gener
threshold
cycl
ct
valu
ct
cutoff
valu
sampl
consid
posit
sampl
consid
neg
transcript
express
empir
select
posit
control
cdna
cho
cell
express
either
fulllength
cea
cho
fl
cea
cea
splice
variant
cho
sv
cea
use
complementari
dna
isol
dhfrdefici
cho
cell
lack
cea
express
use
neg
control
qpcr
measur
kill
human
tumor
cell
line
control
bite
cell
line
cocultur
enrich
cell
bite
antibodi
describ
cell
lysi
measur
releas
tissu
cultur
media
via
specif
electrochemiluminesc
assay
meso
scale
discoveri
gaithersburg
md
statist
signific
differ
affin
appar
k
cytotox
ec
valu
calcul
use
twotail
parametr
test
calcul
graphpad
prism
softwar
version
window
graphpad
softwar
recogn
full
length
cea
howev
correspond
epitop
unknown
cea
delet
mutant
gener
identifi
domain
cea
bind
fulllength
cea
transcript
ncbi
access
number
contain
exon
intron
encod
amino
acid
aa
protein
compos
aa
process
leader
sequenc
one
igvlik
ntermin
domain
six
immunoglobulin
constant
igc
like
domain
denot
ctermin
aa
peptid
remov
gpi
linkag
figur
five
delet
mutant
construct
remov
follow
igclik
domain
domain
domain
domain
domain
domain
shown
figur
mutant
transient
express
gpianchor
protein
f
cell
bind
anticea
polyclon
control
antibodi
delet
mutant
analyz
use
flow
cytometri
recogn
delet
mutant
lack
domain
figur
bound
well
mutant
contain
figur
addit
igclik
domain
remov
figur
still
recogn
correspond
truncat
cea
protein
level
similar
measur
fulllength
cea
protein
figur
result
suggest
epitop
local
domain
cea
domain
involv
bind
despit
highli
homolog
epitopecontain
domain
therefor
swapmut
construct
exchang
short
segment
domain
correspond
portion
domain
refin
bind
epitop
two
truncat
cea
mutant
engin
use
templat
construct
swap
mutant
mutant
compris
ndomain
domain
gpi
region
align
amino
acid
sequenc
domain
identifi
differ
aa
composit
region
sequenc
divers
divid
three
shorter
segment
label
aa
b
aa
c
aa
figur
six
swap
mutant
gener
swap
segment
b
c
domain
domain
ko
mutant
swap
segment
domain
domain
ki
mutant
shown
figur
bind
ko
ki
mutant
lack
either
c
segment
domain
koa
koc
kia
kib
kic
figur
c
bound
well
swap
variant
encod
c
segment
domain
kob
figur
c
residu
bind
koc
mutant
could
detect
togeth
swapmut
human
cea
amino
acid
sequenc
align
domain
cea
sequenc
homolog
analysi
reveal
amino
acid
differ
two
domain
amino
acid
box
three
segment
b
c
defin
domain
gener
swapmut
b
schemat
display
swap
mutant
construct
exchang
segment
b
c
open
box
grey
box
domain
use
truncat
mutant
templat
encod
ndomain
domain
gpi
region
c
flow
cytometri
analysi
bind
delet
mutant
express
surfac
f
cell
mutant
express
well
monitor
anticea
polyclon
antibodi
bind
well
knockout
ko
knockin
ki
mutant
lack
either
c
segment
domain
koa
koc
kia
kib
kic
bound
well
one
variant
encod
c
segment
domain
kob
lack
bind
koa
mutant
data
indic
segment
c
significantli
contribut
bind
lesser
degre
segment
due
high
degre
ident
segment
b
domain
direct
involv
segment
bind
could
entir
rule
use
swap
mutantbas
approach
howev
unlik
follow
reason
bind
mutant
encod
b
segment
domain
conjunct
either
c
segment
domain
koa
koc
figur
bind
level
mutant
encod
c
segment
domain
kob
compar
signal
fulllength
cea
delet
mutant
figur
model
structur
domain
use
murin
templat
reveal
segment
b
spatial
distal
critic
residu
n
see
follow
section
therefor
swapmut
reveal
bound
nonlinear
epitop
domain
cea
compris
two
segment
name
segment
segment
c
sitedirect
mutagenesi
comput
homolog
model
employ
identifi
critic
residu
within
segment
c
essenti
bind
amino
acid
segment
c
domain
differ
domain
replac
correspond
residu
encod
sever
substitut
time
figur
bind
substanti
decreas
variant
residu
n
mutat
koftn
kone
bound
well
mutant
figur
furthermor
replac
residu
n
either
counterpart
residu
ly
domain
kon
ala
n
abolish
bind
figur
mutat
residu
f
ala
substanti
decreas
bind
f
suggest
also
involv
interact
lesser
extent
residu
n
figur
taken
togeth
data
demonstr
import
f
n
final
sinc
e
encod
koeli
variant
bind
well
conclud
residu
energet
involv
epitop
previous
note
graft
segment
includ
f
n
residu
domain
domain
kia
result
bind
suggest
bind
epitop
compris
addit
critic
residu
point
toward
nonlinear
conform
model
structur
domain
also
reveal
two
cluster
amino
acid
v
g
p
e
n
segment
c
spatial
close
alreadi
identifi
critic
residu
n
segment
figur
observ
suggest
amino
acid
could
contribut
bind
concert
n
knockingout
amino
acid
v
g
p
e
kovgp
n
koin
separ
figur
knockingin
entir
segment
c
includ
cluster
v
g
p
e
n
kic
figur
effect
abolish
restor
bind
respect
howev
knockingout
amino
acid
togeth
reduc
complet
abolish
bind
kovgpein
figur
thu
amino
acid
v
g
p
e
n
segment
c
cea
could
also
involv
bind
possibl
knockout
cea
variant
exhibit
incorrect
fold
near
epitop
region
therebi
lose
bind
capac
therefor
confirm
potenti
epitop
region
identifi
knockout
variant
use
gain
function
knockin
mutant
inde
knock
segment
c
domain
domain
kobkiac
kob
encod
amino
acid
kiac
result
bind
compar
full
length
cea
figur
furthermor
graft
three
amino
acid
f
n
segment
six
amino
acid
v
g
p
e
n
segment
c
domain
kiftnvgpein
also
result
bind
compar
full
length
cea
figur
summari
result
demonstr
epitop
cea
bound
nonlinear
conform
epitop
locat
domain
cea
compris
two
segment
amino
acid
critic
amino
acid
f
n
v
g
p
e
n
residu
n
may
contribut
bind
sinc
mutat
alon
complet
disrupt
interact
figur
bind
matur
fulllength
cea
howev
polymorph
andor
isoform
cea
may
alter
bind
epitop
neg
affect
abil
bind
epitop
cea
bound
identifi
abil
recogn
cancer
cell
express
polymorph
isoform
cea
could
evalu
polymorph
cea
survey
use
ncbi
singlenucleotid
polymorph
snp
databas
http
wwwncbinlm
nihgovprojectssnp
two
nonsynonym
code
snp
cea
identifi
bind
epitop
shown
figur
singlenucleotid
c
chang
snp
result
amino
acid
chang
ala
asp
aa
posit
singlenucleotid
g
chang
snp
encod
aa
chang
glu
ly
aa
posit
accord
snp
databas
minor
allel
frequenc
popul
minor
allel
frequenc
popul
respect
howev
minor
allel
homozygos
rate
close
european
asian
popul
subsaharan
african
popul
minor
allel
homozygos
rate
differ
popul
sinc
homozygos
rate
snp
low
anticip
identifi
cea
snp
littl
impact
bind
cea
popul
addit
nation
center
biotechnolog
inform
ncbi
genbankh
databas
http
wwwncbinlmnihgov
genbank
search
splice
variant
cea
singl
splice
variant
ncbi
access
number
colon
cancer
tissu
identifi
transcript
use
altern
splice
donor
site
exon
skip
exon
thu
translat
transcript
result
aa
protein
infram
truncat
amino
acid
fulllength
cea
truncat
delet
small
portion
ntermin
domain
entir
domain
larg
portion
domain
figur
splice
variant
sequenc
code
process
leader
sequenc
ctermin
peptid
expect
remov
gpi
linkag
similar
manner
fulllength
cea
undergo
similar
posttransl
modif
fulllength
cea
predict
matur
gpianchor
membran
protein
amino
acid
anoth
put
cea
splice
variant
involv
novel
splice
exon
interven
intron
sequenc
detect
peripher
blood
colon
cancer
patient
revers
transcript
pcr
howev
sequenc
within
middl
part
bp
pcr
product
base
pair
put
cea
isoform
isol
white
blood
cell
match
part
genom
sequenc
cea
therefor
pcr
product
like
repres
pcr
artifact
real
cea
splice
form
consequ
investig
put
cea
splice
variant
biolog
function
distribut
cea
splice
variant
normal
cancer
tissu
unknown
determin
express
frequenc
fulllength
cea
splice
variant
transcript
normal
cancer
human
tissu
realtim
qpcr
perform
use
rna
isol
frozen
primari
human
pancreat
tissu
cdna
gener
frozen
colorect
lung
breast
pancreat
tissu
purchas
form
multitissu
cdna
array
analysi
use
sequencespecif
primer
specif
amplifi
either
fulllength
cea
cea
splice
variant
sequenc
result
tabl
qpcr
analysi
use
frozen
primari
pancreat
tissu
specimen
demonstr
fulllength
cea
transcript
detect
normal
human
pancreat
tissu
among
diseas
tissu
full
length
transcript
found
frequent
pancreat
adenocarcinoma
less
frequent
benign
adenoma
pancreat
endocrin
tumor
although
total
number
specimen
repres
latter
two
categori
small
transcript
cea
splice
variant
detect
normal
pancreat
tissu
benign
adenoma
endocrin
tumor
rare
detect
pancreat
adenocarcinoma
express
cea
splice
variant
transcript
singl
posit
adenocarcinoma
specimen
concord
fulllength
cea
transcript
express
tabl
result
qpcr
analysi
use
human
tissu
cdna
array
tabl
tabl
thu
express
cea
splice
variant
transcript
vari
differ
cancer
howev
alway
coexpress
fulllength
cea
transcript
although
cea
splice
variant
infrequ
found
pancreat
tumor
found
high
frequenc
colorect
gastroesophag
cancer
lesser
degre
lung
breast
tumor
due
concord
express
full
length
cea
human
tumor
sought
understand
bind
cea
splice
variant
role
cea
isoform
might
play
target
ceaposit
tumor
amino
acid
fulllength
cea
import
bind
found
larg
absent
cea
splice
variant
except
amino
acid
n
segment
c
figur
observ
suggest
bind
cea
splice
variant
unlik
occur
test
hypothesi
cho
cell
infect
lentiviru
construct
direct
express
fulllength
cea
cho
fl
cea
cea
splice
variant
cho
sv
cea
concurr
sequenti
infect
cell
cea
splice
variant
fulllength
cea
cho
flsv
cea
fulllength
cea
cea
splice
variant
protein
express
verifi
western
blot
figur
anticip
bound
cell
express
fulllength
cea
cell
express
cea
splice
variant
figur
note
higher
level
bind
observ
cell
express
cea
splice
variant
full
length
cea
togeth
rel
cell
express
full
length
cea
like
due
differ
level
express
effici
independ
infect
cell
line
although
effect
cea
splice
variant
protein
full
length
cea
protein
level
epitop
access
cell
rule
zhou
et
al
show
ntermin
domain
mediat
interact
cea
molecu
appos
cell
surfac
domain
present
within
cea
splice
variant
thu
test
hypothesi
coexpress
cea
splice
variant
fulllength
cea
protein
may
heterophil
interact
result
bind
epitop
mask
fulllength
form
subsequ
prevent
reduc
bind
coexpress
cea
splice
variant
fulllength
cea
cell
significantli
affect
appar
bind
affin
fulllength
cea
cho
fl
cea
appar
k
nm
cho
flsv
cea
appar
k
nm
p
result
expect
sinc
homophil
interact
fulllength
cea
protein
also
appear
prevent
bind
ceaspecif
bite
antibodi
consist
bind
data
cho
sv
cea
trigger
activ
cell
healthi
donor
presenc
measur
upregul
protein
either
cell
figur
cell
activ
marker
shown
previous
correl
tempor
releas
cytokin
cell
activ
bite
antibodi
likewis
also
mediat
lysi
target
cell
express
splice
variant
figur
contrast
activ
cell
induc
kill
cho
fl
cea
cho
flsv
cea
cell
similar
level
potenc
ec
valu
cho
fl
cea
ec
ngml
cho
flsv
cea
ec
ngml
p
somewhat
higher
maxim
cell
activ
maximum
achiev
cytotox
level
observ
cho
flsv
cea
cell
rel
cho
fl
cea
cell
may
explain
higher
full
length
cea
express
former
describ
studi
full
length
cea
splice
variant
carri
cho
cell
due
eas
infect
lentivir
construct
subsequ
select
ceaexpress
cell
use
flow
cytometri
demonstr
kill
specif
cea
posit
human
tumor
cell
examin
numer
human
cancer
cell
line
cea
express
abil
kill
activ
cell
consist
specif
observ
cho
cell
mediat
kill
human
tumor
cell
express
cea
express
cell
surfac
cea
figur
addit
control
bite
induc
cell
lysi
cea
posit
neg
cell
line
provid
insight
ceatarget
diagnost
therapi
understand
specif
anticea
mab
mani
effort
made
character
bind
epitop
antibodi
use
variou
approach
extens
investig
involv
classif
anticea
mab
five
distinct
epitop
gold
epitop
competit
bind
analysi
studi
correl
gold
epitop
domain
cea
use
differ
cea
fragment
construct
howev
precis
local
epitop
amino
acid
sequenc
level
attempt
identifi
amino
acid
sequenc
correspond
gold
epitop
use
synthet
overlap
fifteenm
peptid
fail
suggest
gold
epitop
conform
addit
immunohistochemistri
immuno
flow
cytometri
use
demonstr
good
correl
gold
epitop
group
bind
specif
mab
bind
gold
epitop
gener
specif
cea
react
colon
carcinoma
normal
colon
mucosa
normal
gastric
foveola
mab
epitop
highli
crossreact
differ
normal
tissu
possibl
due
bind
cearel
antigen
specif
crossreact
mab
found
epitop
map
epitop
ceaspecif
arm
domain
compris
two
stretch
amino
acid
interestingli
epitop
cea
belong
gold
epitop
local
domain
identifi
ceaspecif
epitop
group
cea
compris
highli
repetit
immunoglobulin
domain
anticea
mab
bind
repetit
epitop
cea
highli
crossreact
lack
specif
cea
anticea
arm
human
version
murin
antibodi
shown
specif
bind
cea
character
epitop
led
us
propos
critic
residu
f
n
mediat
fine
specif
cea
due
uniqu
domain
cea
compar
immunoglobulin
domain
cea
relat
molecul
ceacam
famili
includ
identifi
bind
epitop
evalu
impact
polymorph
isoform
domain
cea
activ
two
nonsynonym
snp
identifi
bind
epitop
occur
low
frequenc
gener
popul
consid
littl
impact
bind
cea
addit
singl
splice
variant
identifi
lack
portion
domain
critic
bind
effort
understand
associ
splice
variant
express
diseas
found
express
occur
substanti
percentag
primari
human
colorect
gastroesophag
tumor
lesser
extent
lung
breast
tumor
pattern
concord
full
length
cea
express
howev
sinc
bind
cea
splice
variant
due
loss
antibodybind
epitop
clear
splice
variant
target
primari
human
tumor
also
express
full
length
cea
cea
could
particip
homotyp
interact
adjac
cell
remain
possibl
express
cea
splice
variant
may
interfer
bind
subsequ
tumor
cell
lysi
interact
full
length
cea
coexpress
cea
splice
variant
full
length
cea
formal
demonstr
case
bind
full
length
cea
potenc
ceadirect
lysi
significantli
affect
simultan
express
splice
variant
full
length
cea
therefor
express
cea
splice
variant
primari
human
tumor
cell
anticip
interfer
bind
fulllength
cea
inhibit
tcell
kill
tumor
cell
express
fulllength
cea
howev
discrimin
fulllength
cea
cea
splice
variant
may
import
monitor
statu
cea
posit
tumor
via
chang
serum
cea
level
clinic
studi
patient
receiv
figur
western
blot
cea
protein
express
cho
cell
line
fulllength
cea
protein
indic
fill
arrowhead
cea
splice
variant
open
arrowhead
protein
detect
use
mab
molecular
weight
kilodalton
kda
protein
standard
indic
left
imag
lane
cho
fl
cho
flsv
cell
lysat
contain
band
kda
presum
nonglycosyl
form
cea
equal
amount
protein
load
lane
gel
control
detect
